單抗研發(fā)及理化表征分析Monoclonal Antibody Development and Ph

本文格式為Word版，下載可任意編輯——單抗研發(fā)及理化表征分析MonoclonalAntibodyDevelopmentandPh70mMsaltandcanbeproportionedover30-40%ofthepumprange,wellwithinthecapabilitiesofmodernpumps.Oftenagradientholdfor5minutesattheinitialsaltconcentrationisincluded,justincaseamethodisparticularlysensitivewhenbeingtransferredfromoneequipmenttypetoanother.Insuchcasestheholdtimecanbeadjustedtocompensatefordifferencesinthegradientdelayvolumebetweentheinstruments.

Temperaturesinsidethecolumnaredependentonovendesignandplumbingconfiguration.Havingapre-columnheatexchangerinlineoroutoflinecouldmakeaseveraldegreedifferenceinthetemperatureatwhichthecolumnchemistryoccurs.ThisisparticularlyconcerningforbufferswithwhichthepHcanchangerapidlywithtemperature.Figure14showsacomparisonofcolumncompartmenttemperaturesettingsfortwodifferentinstrumentsfromdifferentmanufacturers.Tomakethecorrelation,thermocoupleswerefittedintoT-piecesinthefluidpathinsidethecolumnoven,butjustpriortothecolumn,andtemperaturesweremeasuredforarangeofcolumncompartmentsetpointsandmobilephaseflowrates.Thesemeasurementswereusedtoestimatethetemperatureofmobilephasegoingthroughthecolumnforeachsetpoint.Byequatingthemeasuredfluidtemperaturesforeachflowrate,thecorrelationofcolumncompartmenttemperatureswereplotted.Itisnotedinthiscorrelationthattherewasalsoasignificanteffectofthemobilephaseflowrateonthecorrelation.

Differentdetectorscansometimesyielddifferencesinbaselineslope.Thiscanoccurwhenmovingfromasingle/doublewavelengthdetectorwithareferencebeamtoaphotodiodearray(PDA)detector.TheselectionofanappropriatereferencewavelengthandbandwidthonthePDAcanovercomedetectorvariance.

Fig.14.ComparisonofcolumncompartmenttemperaturesettingsrequiredtoachievethesamecolumnscompartmenttemperaturefortwodifferentHPLCmodelsatdifferentflowrates.Resultsareshownfora4x250mmDionexProPaccolumn.TheAgilent1100HPLCwasconfiguredusingonlythelefthandsideheatexchanger.TheWaters2695HPLCwasconfiguredwiththesolventpre-heaterin-line.

.

458

11.2Methodvalidation

InnovationsinBiotechnology

Beforeananalyticalmethodcanbeincorporatedintoacharacterizationplatformoraqualitycontrolsystem,itmustfirstbedemonstratedthatthemethodissuitableforitsintendedpurpose.GuidelinesforvalidationofanalyticalmethodshavebeenpublishedintheUnitedStatesPharmacopeia,bytheInternationalConferenceonHarmonization(ICH),USFoodandDrugAdministration(FDA),andinpublishedreviews(Bakshi&Singh,2023).Methodsmustbeevaluatedconsideringregulatoryrequirementsandvalidationprocedures.Inotherwords,the“validatability〞ofthesemethodsmustbeassessedbeforeimplementation.Validationtestsincludeprecision,accuracy,andlinearity.Intermediateprecisionistestedbyusingmultipleinstruments,multipleanalysts,andmultiplecolumnlots.Methodsmustbevalidatedanddocumentedaccordingtoregulatoryrequirementspriortoimplementationintoacontrolsystemforlotreleaseofdrugsubstanceanddrugproduct.Robustnessstudiescanalsobeperformedinconjunctionwithmethodvalidation.Ithasbeenourexperiencethatthemostsignificanteffectsonmethodrobustnessare:mobilephasepHvalue,columntemperature,metalcontaminationandcolumnage.

Asystemsuitabilityrangecanbeobtainedfromrobustnessstudies.Thisrangeisoftenbasedonthestandarddeviationofthemeanforaparticularmeasuredcomponent,suchasmainpeakrelativearea.Thesystemsuitabilityrangeindicatestheprecisionofthemethod.pH-IECmaydemonstrateanimprovementinprecisionoverconventionalsalt-basedIEC(Reaetal.,2023).The6σrangesinFigure15,whichpredictsa99%methodsuccessrate,demonstratetheimprovedprecisionofthepH-gradientIECmethodoverconventionalIEC,whichcanhavea6σrangeofupto8%mainpeakrelativearea(Figure15).

Fig.15.Sixsigmarange(±3SD)formainpeakrelativeareaforsaltgradientIEC(diamonds)andpHgradientIEC(circles)foravarietyofmAbs.

.

464

InnovationsinBiotechnology

Vlasak,J.,&Ionescu,R.(2023).HeterogeneityofMonoclonalAntibodiesRevealedby

Charge-SensitiveMethods.CurrentPharmaceuticalBiotechnology,Vol.9,No.6,(December2023),pp.468–481,ISSN1389-2023

Waldmann,T.A.(2023).Immunotherapy:Past,PresentandFuture.NatureMedicine,Vol.9,

No.1,(January2023),pp.269-277,ISSN1078-8956

Weitzhandler,M.,Farnan,D.,Horvath,J.,Rohrer,J.S.,Slingsby,R.W.,Avdalovic,N.,&

Pohl,C.(1998).ProteinVariantSeparationsUsingCationExchangeChromatographyonGrafted,PolymericStationaryPhases,JournalofChromatographyA,Vol.828,No.1-2,(December1998),pp.365-372,ISSN0021-9673

Yang,Y.,Strahan,A.,Li,C.,Shen,A.,Liu,H.,Ouyang,J.,Katta,V.,Francissen,K.&Zhang,

B.(2023).DetectingLowLevelSequenceVariantsinRecombinantMonoclonalAntibodies.MAbs,Vol.2,No.3,(May/June2023),pp.285–298,ISSN1942-0870

Ziegelbauer,K.,&Light,D.R.(2023).MonoclonalAntibodyTherapeutics:Leading

CompaniestoMaximiseSalesandMarketShare.JournalofCommercialBiotechnology,Vol.14,No.1,(January2023),pp.65-72,ISSN1462-8732

.

InnovationsinBiotechnologyEditedbyDr.EddyC.AgboISBN978-953-51-0096-6Hardcover,474pagesPublisherInTechPublishedonline17,February,2023PublishedinprinteditionFebruary,2023InnovationsinBiotechnologyprovidesanauthoritativecrystallizationofsomeoftheevolvingleading-edgebiomedicalresearchtopicsanddevelopmentsinthefieldofbiotechnology.Itisaptlywrittentointegrateemergingbasicresearchtopicswiththeirbiotechnologyapplications.Italsochallengesthereadertoappreciatetheroleofbiotechnologyinsociety,addressingclearquestionsrelatingtobiotechpolicyandethicsinthecontextoftheresearchadvances.Inaneraofinterdisciplinarycollaboration,thebookservesanexcellentindepthtextforabroadrangeofreadersrangingfromsocialscientiststostudents,researchersandpolicymakers.Everytopicweavesbacktothesamebottomline:howdoesthisdiscoveryimpactsocietyinapositiveway?HowtoreferenceInordertocorrectlyreferencethisscholarlywork,feelfreetocopyandpastethefollowing:JenniferC.Re